ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral ...

Shilpa Medicare’s equal joint venture with Zydus group - Oncosol - along with its partner company Shorla Oncology, has announced USFDA's approval for IMKELDI, the first oral liquid form of imatinib to ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

Oncosol, along with its partner Shorla Oncology, has received US Food and Drug Administration (USFDA) approval for IMKELDI (imatinib oral solution) to treat leukemia and other cancers.

Shilpa Medicare's Joint Venture Oncosol, along with its partner Shorla Oncology, on Wednesday announced that the US FDA has ...

FDA has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor for treating leukemia and a range of cancers, including CML, GIST, and Ph+ ALL. Developed by Shorla Oncology ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Imkeldi is supplied as a strawberry-flavored oral solution in a 140 mL, child-resistant, tamper-evident bottle.

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...